当前位置:药药网 / 数据中心 / 生物制药海外临床研究状况
RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial
标题(英文)
RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial
条件
Multiple Sclerosis, Relapsing-Remitting
干预
Biological: RC18 160mg|Biological: RC18 240mg